David Bland, MBBS Head, Medicine, Pulmonary & Critical Care Div School of Medicine Associate Professor, Medicine School of Medicine

Research & Grantsmanship 

  Funded Research Project (CI)

• A phase 2 study to evaluate dose and duration of treatment of drotrecogin alfa (activated) using serial measurements of protein C in patients with sever sepsis and multiple organ dysfunction ( 1/2007 - 1/2008 )

• A phase 3, multicenter, randomized, placebo controlled, double blind, three arm study to evaluate the safety and efficacy of tifacogin (Recombinant tissue factor pathway inhibitor) administration in subjects with severe community acquired pneumonia ( 1/2006 - 1/2007 )